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Pleomorphic dermal sarcoma of the scalp:
Review of management and distinguishing
features from atypical fibroxanthoma
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Neda Nikbakht, MD, PhD
Key words: atypical fibroxanthoma; dermatopathology; management; pleomorphic dermal sarcoma.

INTRODUCTION
Pleomorphic dermal sarcoma (PDS) and atypical
fibroxanthoma (AFX) are unusual and rare tumors of
the tissue mesenchyme. Because the morphology
and clinical presentation of PDS and AFX are similar,
there is disagreement over whether AFX and PDS are
separate clinical conditions or variants of the same
condition. Researched and studied far more heavily
than PDS, AFX typically affects elderly patients and
those with excessive sun exposure.1 Several other
risk factors for AFX include organ transplantation,
radiation, and xeroderma pigmentosum.2,3
Although PDS shares histopathologic characteristics with AFX, PDS presents with a more aggressive
clinical course, including the potential for metastases
and recurrence.4 Because of the rare occurrence of
PDS, the exact histogenesis, clinical course, and
treatment have yet to be elucidated. Here, we report
a case of PDS, affecting the scalp of an elderly man
and provide a review of the literature focused on the
diagnosis and treatment of PDS as well as its
distinction from AFX.

CASE REPORT
A 72-year-old white male presented to the dermatology clinic for evaluation of a new scalp lesion of 1week duration. The patient reported intermittent
bleeding with mechanical irritation but denied pain
or pruritus. On examination, he had a soft, pink-topurple, ulcerated, ill-defined nodule with hemorrhagic crusting measuring approximately 2.5 cm on
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the vertex scalp (Fig 1, A). A shave biopsy of the
lesion was performed, and histologic examination
revealed a dermal neoplasm with pleomorphic
spindle-shaped to epithelioid cells, enlarged
nuclei, prominent nucleoli, and several atypical
mitotic figures extending to the base of the lesion
(Fig 2, A and B). The neoplasm was stained
strongly with CD10 and faintly with CD163 and
smooth muscle actin. S100, avian v-ets erythroblastosis virus E26 oncogene homolog (ERG), and pancytokeratin (PANCKER) stains were negative (Fig 2,
C-H ). These histologic findings, including margin
involvement by the tumor, and the clinical findings
of lack of definition, asymmetry, and size [2 cm,
raised concern for PDS. Given this concern, a
positron emission tomography/computed tomography scan was performed to rule out distant
metastasis and revealed no lymph node or systemic
involvement.
The lesion was treated with wide local excision
with 3-cm margins to the level of the pericranium
(Fig 1, B). Resection sized the residual tumor at
1.5 cm with an invasion into subcutaneous tissue
with a mitotic rate of 10 mitoses per 10 high-power
fields, histologic grade 2, and tumor staging of T1.
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Fig 1. A, Initial presentation; pink-to-purple, ulcerated, ill-defined nodule with hemorrhagic
crusting measuring approximately 2 cm on the posterior aspect of vertex of the scalp. B, Oneweek following wide local resection and O-Z flap repair; well-healing incision with sutures in
place. C, Four-months postoperation; well-healed incision with slight atrophy.

Fig 2. A, There is a dense, nodular proliferation within the dermis with a lateral collarette and
epidermal ulceration. B, High-power view shows pleomorphic spindle-shaped and epithelioid
cells with enlarged hyperchromatic nuclei, prominent nucleoli, and several mitotic figures.
C-H, The neoplasm highlights strongly with CD10 and faintly with CD163 and smooth muscle
actin stains. ERG, pancytokeratin (PANCKER), and S100 stains are negative. (A and B,
Hematoxylin-eosin stain; original magnifications: A, 310; B, 3100; C, CD10 stain; original
magnification: C, 310; D, CD163 stain; original magnification: D, 310; E, SMA stain; original
magnification: E, 310; F, ERG stain; original magnification: F, 310; G, PANCKER stain; original
magnification: G, 310; H, S100 stain; original magnification: H, 310.)

The presence of neoplastic invasion into the subcutaneous fat and overall immunohistochemical and
histopathology presentation supported the diagnosis

of PDS. Because the procedure yielded negative
resection margins, adjuvant radiotherapy was not
indicated.
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Within 4 months of excision, he presented for
follow-up with a well-healed surgical site without
clinical evidence of recurrence (Fig 1, C ). Although
there are no standardized management guidelines
for PDS, follow-up appointments were planned
every 6 months for the next 3 years and annually
thereafter based on the National Comprehensive
Cancer Network’s 2022 clinical practice guidelines
for soft-tissue sarcomas.5

DISCUSSION
The precise definitions, diagnostic criteria, and
terminology of PDS and its related neoplasms are a
topic of extensive debate. Historically, the terms AFX
and malignant fibrous histiocytoma (MFH) were
used on a spectrum, with more superficial and
deeper tumors termed AFX and MFH, respectively.
As histologic techniques advanced, many tumors
that were previously classified as MFH were found to
be falsely diagnosed and recategorized to other types
of tumors. As such, the term MFH has become
antiquated and replaced by the term undifferentiated
pleomorphic sarcoma. To further complicate matters, it is argued that the term PDS better describes
tumors of cutaneous origin because the term undifferentiated pleomorphic sarcoma also includes a
variety of malignant soft-tissue neoplasms.6
Because PDS presents with an aggressive clinical
course, including a high rate of metastasis, a high
chance of recurrence, and deep tissue invasion, the
need for a timely and accurate diagnosis is
apparent.7,8 Histologically, AFX and PDS share
similar immunohistochemical profiles. The major
distinguishing features of PDS are the presence of
tumor necrosis, lymphovascular invasion, and perineural infiltration.7 In addition, AFX presents with
proximity to the epidermis with limited depth of
invasion, whereas PDS’s presentation is diffusely
infiltrative with more aggressive histopathologic
behavior.7,8 Clinical distinguishing features include
a typically \2 cm lesional size for AFX and a larger
lesional diameter for PDS. Furthermore, PDS is
commonly ill-defined and asymmetric, whereas
AFX often presents as well-defined lesions.7,8
At this time, there are no published guidelines on
the management and follow-up of PDS.9 However,
general management guidelines for soft-tissue sarcomas may be used for reference. Surgical treatment
with wide location excision remains the first-line
therapy for PDS.4 Although specific guidelines for
margin control are not well established, recent data
suggest that 95% of cutaneous undifferentiated
pleomorphic sarcoma tumors can be cleared with
uniform peripheral surgical margins of 3 cm.10

For patients with surgically treated low-grade softtissue sarcomas of the head and neck with negative
margins, the National Comprehensive Cancer
Network’s recommends follow-up every 3 to 6 months
for the first 2 to 3 years, and annually thereafter.5
Imaging of the primary site may not be required in
situations where the area is easily followed by a
physical examination. Patients with advanced disease
and those for whom negative surgical margins cannot
be achieved should be considered for reresection or
adjuvant radiotherapy to decrease the risk of local
recurrence. Although no imaging guidelines exist for
AFX or PDS, imaging may be particularly useful in
PDS to evaluate local infiltration before surgery
because of the higher risk of metastasis.
The potential for metastases and recurrence vary
significantly among PDS and AFX. For PDS, the rate
of metastasis is between 8.8% and 20%, whereas AFX
has a metastatic potential of 1% to 2%.4 Following
treatment, the PDS recurrence rate is 17% to 35%,
whereas AFX has a recurrence rate of 4.6% to 11.3%.
We present a case of PDS occurring on the scalp of
a 72-year-old male patient, successfully treated with
wide local excision. This case highlights the morphologic and histologic characteristics of PDS and
discusses what is known about the management of
this uncommon malignancy.
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